Full title: A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Phase: 2 -3
This is a stage 2 -3 study. Patients with advanced unresectable dedifferentiated liposarcoma are randomized to a study treatment. This is either selinexor (60mg) or a placebo (sugar pill). The study runs over six week cycles (42 days). During this time, the study treatment (either selinexor or a placebo) will be given on Day 1 and Day 3 during weeks 1-6.